EYLEA\u00ae is the commercial brand name of Aflibercept Intravitreal Solution, developed by Bayer. It is a recombinant fusion protein that binds to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), blocking their binding to corresponding receptors, inhibiting pathological neovascularization and reducing vascular permeability in ocular lesions.<\/p>\n\n\n\n
Main Indications<\/strong> Common Side Effects<\/strong> Approval Status in China<\/strong> Buy EYLEA (Aflibercept Intravitreal Solution)\u00a0online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" EYLEA\u00ae is the commercial brand name of Aflibercept Intravitreal Solution, developed by Bayer. It is a recombinant fusion protein that binds to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), blocking their binding to corresponding receptors, inhibiting pathological neovascularization and reducing vascular permeability in ocular lesions. Main IndicationsNeovascular (wet) age-related macular degeneration (nAMD);Macular […]<\/p>\n","protected":false},"author":4,"featured_media":4268,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[101],"tags":[],"class_list":["post-4267","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-news"],"blocksy_meta":[],"yoast_head":"\n
Neovascular (wet) age-related macular degeneration (nAMD);
Macular edema secondary to diabetic retinopathy (DR) or central retinal vein occlusion (CRVO);
Diabetic macular edema (DME);
Myopic choroidal neovascularization (mCNV).<\/p>\n\n\n\n
Common mild adverse reactions: Conjunctival hemorrhage, eye pain, intraocular pressure elevation, vitreous floaters, cataract and corneal abrasion;
Severe but uncommon risks: Endophthalmitis, retinal detachment, severe intraocular inflammation and irreversible visual loss.<\/p>\n\n\n\n
EYLEA\u00ae (specification 114.3 mg\/ml, single dose 8 mg\/0.07 ml) was approved for marketing in China in 2018. It is a prescription ophthalmic injection drug included in China\u2019s Category B medical insurance catalogue.<\/p>\n\n\n\n